Total amount raised
$112 Million
Latest funding date
10/01/2024
Location
AvenCell has successfully raised funding over two rounds, with the latest being a grant round led by AMED and Blackstone Life Sciences. The company is dedicated to developing next-generation immunotherapies for hard-to-treat cancers, utilizing proprietary platforms like the Universal Switchable CAR and Allogeneic platforms.
Keep reading to explore the intricacies of AvenCell's fundraising journey and the investors backing this innovative healthcare company.
What Is AvenCell?
AvenCell Therapeutics, based in Watertown, Massachusetts, is a private company in the biotechnology and immunotherapy industry. The company is dedicated to developing next-generation immunotherapies for hard-to-treat cancers, utilizing proprietary platforms like the Universal Switchable CAR and Allogeneic platforms.
Founded with a focus on deep science and patient needs, AvenCell has grown to employ between 51 and 100 people. The company is guided by a distinguished board of industry experts and has successfully raised funding through grants, with notable investors including AMED and Blackstone Life Sciences.
How Much Funding Has AvenCell Raised?
- Grant Round
- Amount Raised: USD 40,000,000
- Date: June 2025
- Lead Investors: AMED
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance the development of next-generation immunotherapies for hard-to-treat cancers.
- Series B Round
- Amount Raised: USD 112,000,000
- Date: October 2024
- Lead Investors: Novo Holdings
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the clinical validation of AvenCell's Universal Switchable CAR-T cell therapy platform.
Total amount raised: USD 152,000,000. Current valuation: Not publicly disclosed.
Key Investors
- AMED
- Details: The Japan Agency for Medical Research and Development (AMED) is a Japanese government agency that supports medical research and development. AMED has been a lead investor in multiple grant funding rounds for AvenCell.
- Investment Focus Areas: Medical research, healthcare innovation, biotechnology.
- Notable Investments: AvenCell.
- Novo Holdings
- Details: Novo Holdings is a global life sciences investor that focuses on companies transforming care solutions to enhance patient outcomes. Michael Bauer, a partner at Novo Holdings, will join AvenCell's Board of Directors.
- Investment Focus Areas: Life sciences, healthcare, biotechnology.
- Notable Investments: Not publicly disclosed.
- F-Prime Capital
- Details: F-Prime Capital is a venture capital firm that invests in healthcare and life sciences sectors. Nihal Sinha, a partner at F-Prime Capital, will join AvenCell's Board of Directors.
- Investment Focus Areas: Healthcare, life sciences, biotechnology.
- Notable Investments: Not publicly disclosed.
- Eight Roads Ventures Japan
- Details: Eight Roads Ventures Japan is a venture capital firm that focuses on healthcare and technology sectors. They participated in AvenCell's Series B financing round.
- Investment Focus Areas: Healthcare, technology, venture capital.
- Notable Investments: Not publicly disclosed.
- Blackstone Life Sciences
- Details: Blackstone Life Sciences is a founding investor in AvenCell and focuses on transformative healthcare companies. They have continued participation in AvenCell's funding rounds.
- Investment Focus Areas: Life sciences, healthcare, biotechnology.
- Notable Investments: Not publicly disclosed.
What's Next for AvenCell?
With a robust $112 million Series B financing, AvenCell is poised to advance its Universal Switchable CAR-T cell therapy platform. This innovative technology aims to treat a wide range of hematologic malignancies and autoimmune diseases, offering significant growth potential in the biotechnology sector. The company plans to introduce several pipeline candidates over the next two years, addressing unmet patient needs and expanding its market presence.
Future fundraising opportunities appear promising, given the strong backing from high-profile investors like Novo Holdings and F-Prime Capital. As AvenCell progresses through clinical trials, additional funding rounds may be necessary to support further development and commercialization efforts. However, the company faces challenges such as clinical validation, regulatory approvals, and competition from other biotech firms. Navigating these hurdles will be crucial for AvenCell's continued success and potential for strategic partnerships or acquisitions.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like AvenCell and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
